Macrocyclic Depsipeptide Antibiotic Selective for M. tuberculosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tuberculosis, particularly those targeting Mycobacterium tuberculosis, face challenges such as long-term administration of antibiotics disrupting the human gut microbiome and rapid development of antibiotic resistance, necessitating a novel antibiotic with selective activity against M. tuberculosis.
Innovation Solution
Development of a novel macrocyclic depsipeptide compound, represented by Formulae I-IV, which selectively inhibits M. tuberculosis growth and is administered to treat tuberculosis, utilizing a specific transport mechanism through the BacA transporter to target DNA gyrase, differing from existing fluoroquinolone antibiotics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If long-term administration of rifampicin and other antibiotics is used to treat tuberculosis, then bacterial infection is controlled, but human gut microbiome is destroyed and antibiotic-resistant mutants are generated
Solution Approach 1:
The patent applies local quality by designing a macrocyclic depsipeptide compound with specific structural features (macrocyclic ring structure, depsipeptide backbone, specific side chains at positions 3, 7, and 10) that confer selective activity against Mycobacterium tuberculosis while sparing human gut microbiota. The compound's molecular structure is optimized to interact specifically with M. tuberculosis targets, achieving treatment effectiveness without the broad-spectrum harmful effects of conventional antibiotics like rifampicin.
2Reliability
If conventional antibiotics are used to treat tuberculosis, then bacterial growth is inhibited, but rapid development of antibiotic resistance occurs
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of the antibiotic compound—specifically using a macrocyclic depsipeptide framework with optimized side chains at positions 3, 7, and 10. This structural parameter modification results in a compound with enhanced selectivity for M. tuberculosis and reduced affinity for human cells, thereby maintaining antibacterial activity while minimizing the development of resistance through altered binding mechanisms compared to conventional antibiotics.
Data Source
AI summary
The present invention directed to a novel macrocyclic depsipeptide compound, its derivatives, and their pharmaceutically acceptable salts, having selective antibacterial activity against M. tuberculosis.